Glenn serves as a director at Pioneer Group and chairs Alderley Park Ventures. He also holds non-executive directorships at BioAscent, BDD, Health Innovation East Midlands, and Transdermal Diagnostics.
The funding round was backed by the Midlands Engine Investment Fund, Mercia Ventures, and Pioneer Group.
"Our mission is to help companies avoid unnecessary animal testing and provide more accurate and relevant test results. This latest funding will enable us to continue building our range of tests and assays and use our model for different purposes, across different industries. We will also continue engaging with regulators to adapt industry standards tests to become animal free, and establish ImmuONE as a leading provider."
The funding will support new laboratories in Stevenage and headquarters in Milton Keynes alongside team expansion.
"Having worked on drug development projects that involve animal testing, I've seen the difference that new drugs can make to patients' lives. However, I felt there had to be a better way and set out to look for an alternative. Our model not only enables companies to move away from animal testing but also improves safety for patients too. We look forward to working with many more clients and scaling the business with a view to global expansion in the future."
The Nottingham-based eye care specialist raised the capital from investors including Mercia, Pioneer Group, and the University of Nottingham.
"We are delighted to receive further support from our existing investors. This investment round is an endorsement of our innovative new therapies for ocular care and our commitment to developing a rapid and accessible treatment for the ocular injury. The next stage of development is the scaling of our commercial and operational capabilities ahead of a planned Series A round in late 2023 or early 2024,"
The pre-seed round was led by QUBIS Innovation Fund and will support clinical trial preparations and engineering hires.
"We are delighted to have led this investment round into Transdermal Diagnostics. The transdermal approach for glucose monitoring that Transdermal Diagnostics is developing will have a disruptive impact on the diabetes market, we are additionally excited by the company’ potential to expand into the wellness and sports nutrition industries. This funding round alongside the Innovate UK funding will help support them in this journey."
